$ADIA great article write-up! >> Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
Raising the Standard for Stem Cell Therapy – Quality, Safety, Trust.
Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is spearheading a major initiative to establish standardized regulations for umbilical cord stem cell use across the United States. With a focus on quality, safety, and accountability, the company is setting new industry benchmarks that mandate best practices, third-party verification, and homologous applications. These efforts aim to address inconsistencies in stem cell therapies and ensure patient confidence in the emerging field of regenerative medicine.
The Problem: Inconsistent Stem Cell Quality
One of the most pressing issues in the regenerative medicine industry is the lack of standardized quality control. Many clinics provide substandard or even non-viable—so-called "dead"—stem cells without any means for recipients to verify potency or quantity. This inconsistency has eroded trust and prevented patients from fully benefiting from groundbreaking medical advancements.
Adia Med is committed to changing this landscape. "Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."
A Comprehensive Standardization Framework
To ensure every patient receives live, viable stem cells, Adia Med is implementing a robust framework that prioritizes:
1. Homologous Use Standards
Guidelines will be enforced to ensure that stem cells are used in alignment with their natural functions. This approach maximizes safety and efficacy while preventing misuse.
2. Rigorous Quality Control Protocols
Strict procedures for harvesting, processing, and storing stem cells will maintain their therapeutic power. This includes comprehensive donor screening, isolation, and banking methods to uphold the highest standards of care.
3. Third-Party Verification
Every lab offering stem cell products will be required to conduct third-party verification to guarantee a minimum stem cell count and viability for each batch. This will create a transparent, reliable system ensuring patient safety and product integrity.
4. Best Practices Development
By collaborating with stem cell experts, ethicists, and healthcare practitioners, Adia Med will establish industry-wide standards that eliminate variability and improve patient outcomes.
"Doctors should be getting their stem cells from a lab that has a third-party verified, FDA-validated process that guarantees quality," stated Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're pushing to make that the industry baseline with umbilical cord stem cells."
Tackling a Growing Concern
Reports of patients receiving substandard or ineffective stem cells are increasing. Many patients remain unaware that they have received dead cells until they see no results. Adia Med’s verification standards will require all providers to use only live, viable stem cells in guaranteed minimum quantities. The expected benefits include:
Enhanced Patient Safety: Reducing risks associated with poor-quality or improperly used stem cells.
Greater Treatment Consistency: Ensuring reliable results nationwide, regardless of the provider.
Stronger Industry Credibility: Establishing ethical standards to eliminate unregulated and unscrupulous practices.
Federal Collaboration and the Path Forward
To solidify its efforts, Adia Med plans to present its standards to the newly appointed head of the Department of Health and Human Services (DHHS) and the FDA. The company hopes to work closely with federal agencies to align regulatory frameworks and enforce a national standard for umbilical cord stem cell therapies.
"With the leadership of DHHS and the FDA, we can end uncertainty and deliver real benefits to patients across the country," Powalisz emphasized. "By working together, we can ensure that the potential of regenerative medicine is fully realized."
Adia Med is also calling on regulators, medical professionals, and patient advocates to participate in shaping this national framework. Interested parties can learn more and contribute by visiting www.adiamed.com.
CEO Larry Powalisz and ADIA Nutrition’s Growth Vision
Larry Powalisz, CEO of Adia Nutrition, has been at the forefront of innovation in both the supplement and medical sectors. Under his leadership, Adia Nutrition has expanded its focus beyond dietary supplements to include groundbreaking regenerative medicine solutions.
A significant goal for Powalisz and Adia Nutrition is the company's planned uplisting to the OTCQB market. This move would increase transparency, attract institutional investors, and provide greater credibility within the financial markets. "We are working diligently to meet the requirements for an OTCQB uplisting, which will allow us to reach a broader investor base and enhance shareholder value," Powalisz stated.
The planned uplisting aligns with Adia Nutrition’s long-term vision of becoming a leader in both stem cell therapies and holistic health solutions. By securing a stronger market presence, the company aims to accelerate the adoption of its innovative stem cell initiatives while expanding its reach in the healthcare industry.
Conclusion
Adia Med is leading a transformative effort to standardize umbilical cord stem cell use across the United States. With a focus on quality control, third-party verification, and federal collaboration, the company is setting a new benchmark for the regenerative medicine industry. CEO Larry Powalisz remains committed to pushing for these changes while also positioning Adia Nutrition for future growth through its planned OTCQB uplisting.
As Adia Med prepares to present its framework to DHHS and the FDA, the company stands at the forefront of an industry revolution that promises to improve patient outcomes and restore trust in stem cell therapies. Those interested in joining this movement can find further details at www.adiamed.com.
https://allcapresearch.com/penny-stocks/f/adi...ennystocks
Raising the Standard for Stem Cell Therapy – Quality, Safety, Trust.
Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is spearheading a major initiative to establish standardized regulations for umbilical cord stem cell use across the United States. With a focus on quality, safety, and accountability, the company is setting new industry benchmarks that mandate best practices, third-party verification, and homologous applications. These efforts aim to address inconsistencies in stem cell therapies and ensure patient confidence in the emerging field of regenerative medicine.
The Problem: Inconsistent Stem Cell Quality
One of the most pressing issues in the regenerative medicine industry is the lack of standardized quality control. Many clinics provide substandard or even non-viable—so-called "dead"—stem cells without any means for recipients to verify potency or quantity. This inconsistency has eroded trust and prevented patients from fully benefiting from groundbreaking medical advancements.
Adia Med is committed to changing this landscape. "Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."
A Comprehensive Standardization Framework
To ensure every patient receives live, viable stem cells, Adia Med is implementing a robust framework that prioritizes:
1. Homologous Use Standards
Guidelines will be enforced to ensure that stem cells are used in alignment with their natural functions. This approach maximizes safety and efficacy while preventing misuse.
2. Rigorous Quality Control Protocols
Strict procedures for harvesting, processing, and storing stem cells will maintain their therapeutic power. This includes comprehensive donor screening, isolation, and banking methods to uphold the highest standards of care.
3. Third-Party Verification
Every lab offering stem cell products will be required to conduct third-party verification to guarantee a minimum stem cell count and viability for each batch. This will create a transparent, reliable system ensuring patient safety and product integrity.
4. Best Practices Development
By collaborating with stem cell experts, ethicists, and healthcare practitioners, Adia Med will establish industry-wide standards that eliminate variability and improve patient outcomes.
"Doctors should be getting their stem cells from a lab that has a third-party verified, FDA-validated process that guarantees quality," stated Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're pushing to make that the industry baseline with umbilical cord stem cells."
Tackling a Growing Concern
Reports of patients receiving substandard or ineffective stem cells are increasing. Many patients remain unaware that they have received dead cells until they see no results. Adia Med’s verification standards will require all providers to use only live, viable stem cells in guaranteed minimum quantities. The expected benefits include:
Enhanced Patient Safety: Reducing risks associated with poor-quality or improperly used stem cells.
Greater Treatment Consistency: Ensuring reliable results nationwide, regardless of the provider.
Stronger Industry Credibility: Establishing ethical standards to eliminate unregulated and unscrupulous practices.
Federal Collaboration and the Path Forward
To solidify its efforts, Adia Med plans to present its standards to the newly appointed head of the Department of Health and Human Services (DHHS) and the FDA. The company hopes to work closely with federal agencies to align regulatory frameworks and enforce a national standard for umbilical cord stem cell therapies.
"With the leadership of DHHS and the FDA, we can end uncertainty and deliver real benefits to patients across the country," Powalisz emphasized. "By working together, we can ensure that the potential of regenerative medicine is fully realized."
Adia Med is also calling on regulators, medical professionals, and patient advocates to participate in shaping this national framework. Interested parties can learn more and contribute by visiting www.adiamed.com.
CEO Larry Powalisz and ADIA Nutrition’s Growth Vision
Larry Powalisz, CEO of Adia Nutrition, has been at the forefront of innovation in both the supplement and medical sectors. Under his leadership, Adia Nutrition has expanded its focus beyond dietary supplements to include groundbreaking regenerative medicine solutions.
A significant goal for Powalisz and Adia Nutrition is the company's planned uplisting to the OTCQB market. This move would increase transparency, attract institutional investors, and provide greater credibility within the financial markets. "We are working diligently to meet the requirements for an OTCQB uplisting, which will allow us to reach a broader investor base and enhance shareholder value," Powalisz stated.
The planned uplisting aligns with Adia Nutrition’s long-term vision of becoming a leader in both stem cell therapies and holistic health solutions. By securing a stronger market presence, the company aims to accelerate the adoption of its innovative stem cell initiatives while expanding its reach in the healthcare industry.
Conclusion
Adia Med is leading a transformative effort to standardize umbilical cord stem cell use across the United States. With a focus on quality control, third-party verification, and federal collaboration, the company is setting a new benchmark for the regenerative medicine industry. CEO Larry Powalisz remains committed to pushing for these changes while also positioning Adia Nutrition for future growth through its planned OTCQB uplisting.
As Adia Med prepares to present its framework to DHHS and the FDA, the company stands at the forefront of an industry revolution that promises to improve patient outcomes and restore trust in stem cell therapies. Those interested in joining this movement can find further details at www.adiamed.com.
https://allcapresearch.com/penny-stocks/f/adi...ennystocks
